Shin Nippon Biomedical Laboratories, Ltd. (2395) Press Release
Consolidated Financial Results for the Three Months of the Fiscal Year Ending March 31, 2027 (Under Japanese GAAP)
Earlier from Shin Nippon Biomedical Laboratories
- Satsuma Pharmaceuticals and SNBL Announce Publication of Impression of Use and Satisfaction with STS101 (Dihydroergotamine Nasal Powder (Atzumi™)) in Headache
- Satsuma Pharmaceuticals and SNBL Announce Four Abstracts to be Presented at the American Headache Society's 67th Annual Scientific Meeting
- Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi™ (Dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine
- Shin Nippon Biomedical Laboratories: 英語版 株主通信（2023/04/01~2023/09/30）を発行しました